Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs.
The last earnings update was 22 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Altimmune. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Altimmune's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Altimmune has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Altimmune's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Altimmune's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Altimmune's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Altimmune is high growth as no earnings estimate data is available.
Unable to determine if Altimmune is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Altimmune's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Vipin K. Garg, Ph.D. has been President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg served as Advisor of Neos Therapeutics, Inc. since June 27, 2018 until July 31, 2018. Dr. Garg served as the Chief Executive Officer at Neos Therapeutics, Inc. since October 22, 2013 until June 27, 2018 and also served as its President since July 2014 until June 27, 2018. Dr. Garg served as Chief Executive Officer and President at Ocera Therapeutics, Inc., until July 15, 2013. He served as the Chief Executive Officer and President at Tranzyme Pharma, Inc. since February 2000. Dr. Garg has over 25 years of biotechnology industry experience in both technical and management positions. He has a proven track record of building and managing both private and publicly traded companies. He served as Chief Executive Officer and President of Tranzyme, Inc. since February 2000 and served as its Director since October 2000. He served as the Chief Operating Officer of Apex Bioscience Inc. He served as Vice President of Product Development and Manufacturing at DNX Inc. and held management positions at Sepracor Inc. and Bio-Response Inc. (acquired by Baxter). He was a Director of Neos Therapeutics, Inc. since October 22, 2013 until June 27, 2018. Dr. Garg served as a Director at The Council for Entrepreneurial Development. He served as Whole Time Director of Visesh Infotecnics Ltd from August 14, 2012 to January 8, 2014 and served as its Additional Director from February 14, 2011 to September 28, 2011. He served as Director at Ocera Therapeutics, Inc. until July 15, 2013. He served as a Director at Tranzyme Pharma, Inc. since February 2000. Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University of Adelaide, Australia and M.S. Degree from Delhi University.
Insufficient data for Vipin to compare compensation growth.
Vipin's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Altimmune management team is less than 2 years, this suggests a new team.
Acting CFO & Principal Accounting Officer
Chief Medical Officer
Chief Technology Officer
Chief Scientific Officer
Chief Business Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Altimmune board of directors is less than 3 years, this suggests a new board.
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.